Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19‐targeted chimeric antigen receptor T‐cell therapy

Saved in:
Bibliographic Details
Published in:Hematological oncology 2024-01, Vol.42 (1), p.e3221-n/a
Main Authors: Ababneh, Hazim S., Frigault, Matthew J., Patel, Chirayu G.
Format: Article
Language:English
Subjects:
CD19 antigen
Cell therapy
Chimeric antigen receptors
Lymphoma
Mantle cell lymphoma
Radiation therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c3101-51cc17b6ec71f8f58e530b62460d47b75e89ca9f569c0a5f222b82561bbb821f3
container_end_page n/a
container_issue 1
container_start_page e3221
container_title Hematological oncology
container_volume 42
creator Ababneh, Hazim S.
Frigault, Matthew J.
Patel, Chirayu G.
description
doi_str_mv 10.1002/hon.3221
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2863300580</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2863300580</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3101-51cc17b6ec71f8f58e530b62460d47b75e89ca9f569c0a5f222b82561bbb821f3</originalsourceid><addsrcrecordid>eNp1kU1rFTEUhoMo9loFf4EE3LiZek7mzkeWcv2oUCxIXYdM5sydlJnJmGQos_MndNM_6C8xt70qCK4O5Dzn4SUvYy8RzhBAvO3ddJYLgY_YBkHKDKGUj9kGRFVnIHJxwp6FcA2QdlA_ZSd5VVZSbnHD7r7q1upo3cRjT17PK--c53N6oikGfmNjzz0Neg7U8rTx1HltovMrH_UUB-KGhoEP6zj3btR8mVrye2enPd-9R_nzx23Ufk8xXZvejuSt4enO7mlKLkNzUvGrhN1rjhmesyedHgK9OM5T9u3jh6vdeXZx-enz7t1FZnIEzAo0BqumJFNhV3dFTUUOTSm2JbTbqqkKqqXRsitKaUAXnRCiqUVRYtOkiV1-yt48eGfvvi8UohptOATRE7klKFGXeQ5Q1JDQ1_-g127xU0qnhERZ1YgIf4XGuxDSX6nZ21H7VSGoQ1UqVaUOVSX01VG4NCO1f8Df3SQgewBu7EDrf0Xq_PLLvfAXDgagzw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2919781110</pqid></control><display><type>article</type><title>Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19‐targeted chimeric antigen receptor T‐cell therapy</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Ababneh, Hazim S. ; Frigault, Matthew J. ; Patel, Chirayu G.</creator><creatorcontrib>Ababneh, Hazim S. ; Frigault, Matthew J. ; Patel, Chirayu G.</creatorcontrib><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.3221</identifier><identifier>PMID: 37679941</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>CD19 antigen ; Cell therapy ; Chimeric antigen receptors ; Lymphoma ; Mantle cell lymphoma ; Radiation therapy</subject><ispartof>Hematological oncology, 2024-01, Vol.42 (1), p.e3221-n/a</ispartof><rights>2023 John Wiley &amp; Sons Ltd.</rights><rights>2024 John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3101-51cc17b6ec71f8f58e530b62460d47b75e89ca9f569c0a5f222b82561bbb821f3</cites><orcidid>0000-0002-0393-9852</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37679941$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ababneh, Hazim S.</creatorcontrib><creatorcontrib>Frigault, Matthew J.</creatorcontrib><creatorcontrib>Patel, Chirayu G.</creatorcontrib><title>Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19‐targeted chimeric antigen receptor T‐cell therapy</title><title>Hematological oncology</title><addtitle>Hematol Oncol</addtitle><subject>CD19 antigen</subject><subject>Cell therapy</subject><subject>Chimeric antigen receptors</subject><subject>Lymphoma</subject><subject>Mantle cell lymphoma</subject><subject>Radiation therapy</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp1kU1rFTEUhoMo9loFf4EE3LiZek7mzkeWcv2oUCxIXYdM5sydlJnJmGQos_MndNM_6C8xt70qCK4O5Dzn4SUvYy8RzhBAvO3ddJYLgY_YBkHKDKGUj9kGRFVnIHJxwp6FcA2QdlA_ZSd5VVZSbnHD7r7q1upo3cRjT17PK--c53N6oikGfmNjzz0Neg7U8rTx1HltovMrH_UUB-KGhoEP6zj3btR8mVrye2enPd-9R_nzx23Ufk8xXZvejuSt4enO7mlKLkNzUvGrhN1rjhmesyedHgK9OM5T9u3jh6vdeXZx-enz7t1FZnIEzAo0BqumJFNhV3dFTUUOTSm2JbTbqqkKqqXRsitKaUAXnRCiqUVRYtOkiV1-yt48eGfvvi8UohptOATRE7klKFGXeQ5Q1JDQ1_-g127xU0qnhERZ1YgIf4XGuxDSX6nZ21H7VSGoQ1UqVaUOVSX01VG4NCO1f8Df3SQgewBu7EDrf0Xq_PLLvfAXDgagzw</recordid><startdate>202401</startdate><enddate>202401</enddate><creator>Ababneh, Hazim S.</creator><creator>Frigault, Matthew J.</creator><creator>Patel, Chirayu G.</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0393-9852</orcidid></search><sort><creationdate>202401</creationdate><title>Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19‐targeted chimeric antigen receptor T‐cell therapy</title><author>Ababneh, Hazim S. ; Frigault, Matthew J. ; Patel, Chirayu G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3101-51cc17b6ec71f8f58e530b62460d47b75e89ca9f569c0a5f222b82561bbb821f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>CD19 antigen</topic><topic>Cell therapy</topic><topic>Chimeric antigen receptors</topic><topic>Lymphoma</topic><topic>Mantle cell lymphoma</topic><topic>Radiation therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ababneh, Hazim S.</creatorcontrib><creatorcontrib>Frigault, Matthew J.</creatorcontrib><creatorcontrib>Patel, Chirayu G.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ababneh, Hazim S.</au><au>Frigault, Matthew J.</au><au>Patel, Chirayu G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19‐targeted chimeric antigen receptor T‐cell therapy</atitle><jtitle>Hematological oncology</jtitle><addtitle>Hematol Oncol</addtitle><date>2024-01</date><risdate>2024</risdate><volume>42</volume><issue>1</issue><spage>e3221</spage><epage>n/a</epage><pages>e3221-n/a</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37679941</pmid><doi>10.1002/hon.3221</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-0393-9852</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0278-0232
ispartof Hematological oncology, 2024-01, Vol.42 (1), p.e3221-n/a
issn 0278-0232
1099-1069
language eng
recordid cdi_proquest_miscellaneous_2863300580
source Wiley-Blackwell Read & Publish Collection
subjects CD19 antigen
Cell therapy
Chimeric antigen receptors
Lymphoma
Mantle cell lymphoma
Radiation therapy
title Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19‐targeted chimeric antigen receptor T‐cell therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T16%3A08%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiation%20therapy%20for%20patients%20with%20relapsed%20or%20refractory%20mantle%20cell%20lymphoma%20undergoing%20CD19%E2%80%90targeted%20chimeric%20antigen%20receptor%20T%E2%80%90cell%20therapy&rft.jtitle=Hematological%20oncology&rft.au=Ababneh,%20Hazim%20S.&rft.date=2024-01&rft.volume=42&rft.issue=1&rft.spage=e3221&rft.epage=n/a&rft.pages=e3221-n/a&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.3221&rft_dat=%3Cproquest_cross%3E2863300580%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3101-51cc17b6ec71f8f58e530b62460d47b75e89ca9f569c0a5f222b82561bbb821f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2919781110&rft_id=info:pmid/37679941&rfr_iscdi=true